Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2005
10/27/2005WO2005100987A1 Novel ligand of g protein coupled receptor protein and use thereof
10/27/2005WO2005100562A1 OSTEOPONTIN siRNA
10/27/2005WO2005100389A1 Osteoblast growth factor
10/27/2005WO2005100365A1 Thienopyridine derivatives
10/27/2005WO2005099760A1 Solid pharmaceutical preparation
10/27/2005WO2005099759A1 Medicine for prevention and/or treatment of arteriosclerosis
10/27/2005WO2005099686A1 Edible composition having effects of promoting the production and release of calcitonin gene-related peptide
10/27/2005WO2005007699A8 Human antibody molecules for il-13
10/27/2005WO2003023008A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/27/2005US20050240023 Cathepsin cysteine protease inhibitors
10/27/2005US20050240017 5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,11-dihydro-6-oxa-12-thia-dibenzo[a,f]azulen-2-ol; 13-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,13-dihydro-12-oxa-benzo[4,5]cyclohepta[1,2-a]naphthalen-3-ol or derivatives or salts; for alleviating symptoms of estrogen deprivation, including bone loss
10/27/2005US20050239872 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239851 Substituted benzoxazoles as estrogenic agents
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239802 E.g., 6-{2-[5-Chloro-2-(2,4-difluorobenzyloxy)- phenyl]cyclopent-1-enyl}-pyridine-2-carboxylic acid, used to treat prostaglandin mediated diseases that include inflammatory, neuropathic or visceral pain
10/27/2005US20050239796 tert-butyl4-{(3,4-dimethoxyphenethyl)[2-(1H-indol-3-yl)acetyl]amino}-1-piperidine carboxylate; somatostatin receptors modulator; anticarcinogenic agent; acromegalia, hypophyseal adenomas, endocrine gastroenteropancreatic tumors including carcinoid syndrome; reducing amination of N-substituted piperidone
10/27/2005US20050239777 Quinazoline derivatives and pharmaceutical compositions containing them
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239732 Immunostimulatory nucleic acid molecules
10/27/2005US20050239170 Alpha-MSH related compounds and methods of use
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050238693 Process for the preparation and activation of susbstances and a means of producing same
10/27/2005US20050238670 Immunology response intensifiers; administering a bacterial lysate, for inducing an immune response to Staphylococcus aureus infections
10/27/2005US20050238623 Method for treating mammals with modified mammalian blood
10/27/2005CA2562827A1 Thienopyridine derivatives
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/26/2005EP1589100A1 Transcriptional activator
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1588718A1 Gene therapy of hepatocyte growth factor to enhance muscular and cutaneous flap survival
10/26/2005EP1587838A2 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
10/26/2005EP1587803A1 Pyrimidine-4,6-dicarboxylic acid diamides for use as selective mmp 13 inhibitors
10/26/2005EP1587516A1 Amide and ester matrix metalloproteinase inhibitors
10/26/2005EP1587511A2 Treatment of diseases with alpha-7 nach receptor full agonists
10/26/2005EP1587470A2 Improved formulations for transmucosal vaginal delivery of bisphosphonates
10/26/2005EP1430056B1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
10/26/2005EP0625048B2 Synthesis of human procollagens and collagens in recombinant dna systems
10/26/2005CN1688604A Recombinant anti-osteopontin antibody and use thereof
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688572A Piperidinyl targeting compounds that selectively bind integrins
10/26/2005CN1688550A 2, 5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
10/26/2005CN1688549A Compound having TGF-beta inhibitory activity and medicinal composition containing the same
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688527A Fused benzene derivative and use
10/26/2005CN1688294A Enteric composition for the manufacture of soft capsule wall
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224612C Acetylenic sulfonamide thiol TACE inhibitors
10/26/2005CN1224598C Naphthalene derivatives
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/26/2005CN1224419C Orally administered peptides to ameliorate a therosclerosis
10/26/2005CN1224412C Prepared Chinese internal medicine of 'healthy femur'
10/26/2005CN1224409C Medicinal wine for treating prolapse of lumbar intervertebral disc
10/25/2005US6958387 Human serpin polypeptides
10/25/2005US6958353 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
10/25/2005US6958350 Chemical compounds
10/25/2005US6958349 Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/25/2005US6958336 Anticancer agents; immunosuppressants; antiallergens; antiinflammatory agents
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/25/2005US6958220 Inhibitors of proteasomal activity for stimulating hair growth
10/25/2005CA2331053C Compositions and methods for treating conditions responsive to estrogen
10/20/2005WO2005097814A2 Composition and method for inhibiting platelet aggregation
10/20/2005WO2005097775A1 Piperidine derivates for the treatment of chemokines mediared disease
10/20/2005WO2005097151A1 Antioxidant composition and products containing the same
10/20/2005WO2005097150A1 Medicament for relief of symptoms of joint disorders and inflammatory conditions
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234247 New effector conjugates, process for their production and their pharmaceutical use
10/20/2005US20050234245 Estrogen receptor modulators
10/20/2005US20050234129 Salts of nateglinide
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234102 Inhibiting the proteolytic activity of cathepsin S, comprising exposing cathepsin S to compounds such as 1-[4-(5-Chloro-1H-indol-3-yl)-piperidin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol
10/20/2005US20050234090 Modulators of chemokine receptor activity
10/20/2005US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
10/20/2005US20050234079 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234051 5-Substituted 2-aryl-4 pyrimidinones
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234036 3-(2-tetrahydrofuryl-methyl)-2-thioxanthine; neuroinflammatory disorders; pain, cancers, rheumatic arthritis, neurodegenerative diseases
10/20/2005US20050234029 Compounds
10/20/2005US20050234028 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050233999 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
10/20/2005US20050233995 Immunostimulatory nucleic acid molecules
10/20/2005US20050233969 Analogues of GLP-1
10/20/2005US20050233956 Proteins involved in the regulation of energy homeostasis
10/20/2005US20050233452 Cell populations which co-express CD49c and CD90
10/20/2005US20050233417 Growth hormone variations in humans and their uses
10/20/2005US20050232989 Process for preparing oral calcium compositions
10/20/2005US20050232903 Mincing tissue, culturing with growth factors, bone morphogenetic protein or vitamin D; propagating in alginate, agarose and collagen to form 3-dimensional structure
10/20/2005CA2604878A1 Medicament for relief of symptoms of joint disorders and inflammatory conditions
10/20/2005CA2561958A1 Composition and method for inhibiting platelet aggregation
10/20/2005CA2561280A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005CA2561164A1 Steroid sparing agents and their use
10/20/2005CA2560311A1 Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
1 ... 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 ... 820